Ameriprise
FHTX icon

Ameriprise’s Foghorn Therapeutics FHTX Stock Holding History

Ameriprise’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.73M Buy
558,685
+109,709
+24% +$487K ﹤0.01% 2911
2026
Q1 		$2.15M Sell
448,976
-158,694
-26% -$871K ﹤0.01% 2926
2025
Q4 		$3.28M Buy
+607,670
New +$2.75M ﹤0.01% 2737
2025
Q3 		– Sell
-112,237
Closed -$528K – 4096
2025
Q2 		$528K Buy
+112,237
New +$469K ﹤0.01% 3511

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
EC
Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Ameriprise's FHTX Position: Q2 2026 in Review

Ameriprise increased its Foghorn Therapeutics (FHTX) stake by 24% in Q2 2026, buying an estimated $487K and bringing the position to 558,685 shares worth $2.73M. The position accounts for ﹤0.01% of the portfolio, ranked #2911.

Ameriprise first reported a position in FHTX in Q2 2025 and has held it in 4 quarters since. The position peaked at $3.28M in Q4 2025. 103 funds tracked by Wall St. Rank hold FHTX as of Q2 2026.

  • Ameriprise held 558,685 shares of Foghorn Therapeutics worth $2.73M as of Q2 2026.
  • Ameriprise bought 109,709 Foghorn Therapeutics shares in Q2 2026, an estimated $487K.
  • Foghorn Therapeutics made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #2911 holding.
  • Ameriprise first reported a position in Foghorn Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Ameriprise's Foghorn Therapeutics position peaked at $3.28M in Q4 2025.
  • 103 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.